Diseases, Conditions, Syndromes

Proteasome inhibitors show promise for drug-resistant malaria

Proteasome inhibitors have significant promise as components of novel combination therapies to treat multidrug-resistant malaria, according to a study published June 6 in the open-access journal PLOS Pathogens by David Fidock, ...

Oncology & Cancer

Identification of a novel therapeutic target in multiple myeloma

Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed ...

Oncology & Cancer

Researchers shed light on new multiple myeloma therapy

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published ...

Oncology & Cancer

A rare disease inspires a new way to attack cancer

Some of the most promising new treatments for blood cancers, drugs called proteasome inhibitors, have a problem: For reasons that researchers are still working to fully understand, cancer cells can build up a resistance to ...

page 2 from 3